Clinical trials: Control Group
Migraine Headache
A Study to Evaluate the Efficacy and Safety of Erenumab in Adults With Medication Overuse Headache
Study 20170703 is a phase 4, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of erenumab against placebo in participants with chronic migraine (CM) who have a history of at…
- Trial name
- NCT03971071
- Testing
- Erenumab 70 mg, Erenumab 140 mg
- Where
- 94 sites in United States, Australia and 10 more
- Volunteers
- 620 people
- Sponsor
- Amgen
Bipolar Depression
Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Monotherapy)
This clinical study is designed to test the hypothesis that lurasidone is effective, tolerable, and safe for the treatment of patients with bipolar I depression
- Trial name
- NCT00868699
- Testing
- lurasidone
- Where
- 55 sites in United States, Czechia and 6 more
- Volunteers
- 505 people
- Sponsor
- Sumitomo Pharma America, Inc.
Asthma
Evaluation of Tiotropium 2.5 and 5 µg Once Daily Delivered Via the Respimat Inhaler Compared to Placebo in Patient With Moderate to Severe Persistent Asthma
The aim of this trial is to evaluate the safety and efficacy of 2.5 and 5 µg tiotropium over a 52-week treatment period as compared to placebo.
- Trial name
- NCT01340209
- Testing
- Tiotropium Respimat
- Where
- 55 sites in Japan
- Volunteers
- 285 people
- Sponsor
- Boehringer Ingelheim
Diabetes, Type 1, Diabetes, Type 2
Safety of Inhaled Insulin With Type 1 and Type 2 Diabetes
Pulmonary Safety in Diabetics with T/I
- Trial name
- NCT00308737
- Testing
- Technosphere® Insulin Inhalation Powder, Usual Care
- Where
- 176 sites in United States, Canada and 6 more
- Volunteers
- 2,053 people, healthy volunteers welcome
- Sponsor
- Mannkind Corporation
Chronic Kidney Disease, Autosomal Dominant Polycystic Kidney Disease
Efficacy and Safety of Tolvaptan in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease
The purpose of the study is to determine whether tolvaptan is effective and safe for the treatment of late-stage chronic kidney disease due to autosomal dominant polycystic kidney disease (ADPKD)
- Trial name
- NCT02160145
- Testing
- Tolvaptan (OPC-41061)
- Where
- 230 sites in United States, Argentina and 20 more
- Volunteers
- 1,370 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Asthma
A Study of Safety and Efficacy of CNTO 148 in Patients With Severe Persistent Asthma
The purpose of this study is to evaluate the effectiveness and safety of CNTO 148 (golimumab) in patients with severe persistent asthma.
- Trial name
- NCT00207740
- Testing
- CNTO148
- Where
- 57 sites in United States, Belgium and 9 more
- Volunteers
- 309 people
- Sponsor
- Centocor, Inc.
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Safety of Liraglutide Versus Placebo as add-on to Existing Diabetes Medication in Subjects With Type 2 Diabetes and Moderate Renal Impairment
This trial is conducted in Europe and the United States of America (USA). The aim of this trial is to investigate the efficacy and safety of liraglutide in subjects with type 2 diabetes and moderate renal impairment.
- Trial name
- NCT01620489
- Testing
- liraglutide
- Where
- 97 sites in United States, France and 4 more
- Volunteers
- 279 people
- Sponsor
- Novo Nordisk A/S
Arthritis, Rheumatoid
Investigating Clinical Efficacy of Ofatumumab in Adult Rheumatoid Arthritis (RA) Patients Who Had an Inadequate Response to TNF-α Antagonist Therapy
This is a phase III, double-blind, randomized, multicenter, and parallel group trial with a duration of 24 weeks, followed by a 120 week Open-label Period.
- Trial name
- NCT00603525
- Testing
- Ofatumumab
- Where
- 60 sites in Argentina, Denmark and 10 more
- Volunteers
- 169 people
- Sponsor
- GlaxoSmithKline
Cardiac Edema (CHF)
A Dose-ranging Trial of OPC-131461 in Cardiac Edema (Congestive Heart Failure [CHF])
To investigate the dose response in respect of weight decrease following repeated oral administration of OPC-131461 at 1, 2, 5, and 10 mg or placebo in patients with CHF with volume overload despite having received diuretics…
- Trial name
- NCT05615363
- Testing
- OPC 131461 10mg group, OPC 131461 5mg group, OPC 131461 2mg group
- Where
- Japan
- Volunteers
- 157 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Program Sustainability, Tobacco Use
Evaluating and Improving the Sustainability of State-level Tobacco Control Programs in the United States
The purpose of this study is to empirically develop, test, and disseminate sustainability training to improve the institutionalization of evidence-based state tobacco control (TC) programs, and thus, tobacco-related health…
- Trial name
- NCT03598114
- Testing
- Program Sustainability Action Planning Model and Training Curricula
- Where
- United States
- Volunteers
- 255 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Contraception
Study of the Safety and Efficacy of MR-100A-01 in Approximately 1200 Healthy Women for up to 13 Cycles
Study of the contraceptive efficacy, cycle control, safety, and tolerability of MR-100A-01 in approxmiately 1200 women for up to 13 cycles
- Trial name
- NCT05139121
- Testing
- MR-100A-01
- Where
- 100 sites in United States, Canada and 1 more
- Volunteers
- 1,320 people, healthy volunteers welcome
- Sponsor
- Mylan Technologies Inc.
Diabetes Mellitus
Improving Glycemic Control in DM2 Patients in the Ambulatory Setting
More than 10.5% of the US population has diabetes mellitus. The objective of this pilot study is to evaluate whether smart insulin pens combined with CGM devices can improve glucose control in patients with type 2 diabetes (T2D)
- Trial name
- NCT04800471
- Testing
- Smart insulin pens and CGM, Point of Care Glucose Group
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Maryland, Baltimore
Type 2 Diabetes Mellitus (T2DM)
Sitagliptin Mechanism of Action Study in Patients With Type 2 Diabetes Mellitus (0431-059)
A clinical study to determine the safety, efficacy and the way sitagliptin works in patients with Type 2 Diabetes Mellitus who have inadequate glycemic (blood sugar) control.
- Trial name
- NCT00704132
- Testing
- Comparator: sitagliptin phosphate
- Volunteers
- 57 people
- Sponsor
- Merck Sharp & Dohme LLC
Binge Eating Disorder
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The primary objective of the study is to demonstrate the efficacy of SPD489 compared with placebo in adults (18 55 years of age inclusive) with moderate to severe Binge Eating Disorder at Visit 8 (Weeks 11 and 12) as measured by…
- Trial name
- NCT01718509
- Testing
- SPD489 (Lisdexamfetamine dimesylate)
- Where
- 48 sites in United States, Germany
- Volunteers
- 390 people
- Sponsor
- Shire
Cardiac Disease
Exparel in Minimally Invasive Cardiac Surgery
The investigators are presently using Exparel, a slow released local anesthestic, in patients undergoing minimally invasive cardiac surgery.
- Trial name
- NCT02008370
- Testing
- Exparel infiltration
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Maimonides Medical Center
SARS-CoV-2, Influenza
A Study of mRNA-1083 (SARS-CoV-2 and Influenza) Vaccine in Healthy Adult Participants, ≥50 Years of Age
The purpose of this study is to evaluate the immunogenicity, safety, and reactogenicity of mRNA-1083 as compared with active control, co-administered licensed influenza and severe acute respiratory syndrome coronavirus 2 (SARS…
- Trial name
- NCT06097273
- Testing
- mRNA-1083, Influenza Vaccine, COVID-19 Vaccine
- Where
- 146 sites in United States
- Volunteers
- 8,061 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Atrial Fibrillation
Study of DU-176b Aged 80 Years or Older
The purpose of this study is to evaluate the efficacy and safety of edoxaban in patients with non-valvular NVAF aged 80 years or older who are ineligible for available oral anticoagulation therapy.
- Trial name
- NCT02801669
- Testing
- Du-176b
- Where
- 164 sites in Japan
- Volunteers
- 984 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Severe IgE-mediated Asthma
Study to Assess the Efficacy and Safety of Omalizumab Treatment on ICS Reduction for Severe IgE-mediated Asthma
Assess efficacy and safety of omalizumab treatment during 12 months in order to reduce the use of inhaled corticosteroid (ICS) in pediatric and adult participants with severe Immunoglobulin E (IgE)-mediated asthma inadequately…
- Trial name
- MEXIC (NCT01912872)
- Testing
- Omalizumab, Budesonide, Formoterol
- Where
- 21 sites in Mexico
- Volunteers
- 112 people
- Sponsor
- Novartis Pharmaceuticals
Actinic Keratoses
A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on AK on Face or Scalp
This Phase III study is designed to evaluate the efficacy and safety of KX2-391 Ointment in adult participants when applied to an area of skin containing 4-8 stable, clinically typical Actinic Keratosis (AK) lesions on the face…
- Trial name
- AK003 (NCT03285477)
- Testing
- KX2-391 Ointment 1%
- Where
- 30 sites in United States
- Volunteers
- 351 people
- Sponsor
- Almirall, S.A.
Locally Advanced or Metastatic Infantile Fibrosarcoma Harboring an NTRK Gene Fusion, Infantile Fibrosarcoma
A Study Called EPI VITRAKVI to Compare Treatment Results in Patients With Infantile Fibrosarcoma (IFS), a Type of Connective Soft Tissue Cancer, Who Received a Treatment Called Larotrectinib From a Study Called SCOUT With Patient Data From an External Database
This is an observational study in which data from the past of children and young people with a specific cancer, called NTRK gene fusion positive infantile fibrosarcoma (IFS) is studied.
- Trial name
- EPI VITRAKVI (NCT05236257)
- Testing
- Larotrectinib (Vitrakvi, BAY2757556), Standard of Care
- Where
- France
- Volunteers
- 93 people
- Sponsor
- Bayer